Key points are not available for this paper at this time.
Diffuse midline gliomas (DMGs) are lethal pediatric brain tumors. DMG patients are typically treated with radiation in combination with an experimental agent in clinical trials. ONC206 is a novel drug with promising efficacy in preclinical models. Successful clinical translation and deployment of ONC206 requires the identification of companion biomarkers of treatment response. Therefore, the goal of this study was to identify magnetic resonance spectroscopy (MRS)-detectable biomarkers of response to ONC206 in preclinical DMG models. Our studies identify a combination of 1H- and 2H-MRS-detectable biomarkers that serve as imaging biomarkers of early response to ONC206 in mice bearing intracranial DMG xenografts.
Batsios et al. (Wed,) studied this question.